ANXA1 and neoplasm: Additionally, in a recent study, Al-Ali et al. investigated MDX-124, a novel humanized antibody directed against ANXA1, and demonstrated its ability to suppress the growth of ANXA1-expressing tumor cells both in vitro and in vivo by blocking its interaction with FPR1/2 [24].